DE69435235D1 - Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen - Google Patents

Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen

Info

Publication number
DE69435235D1
DE69435235D1 DE69435235T DE69435235T DE69435235D1 DE 69435235 D1 DE69435235 D1 DE 69435235D1 DE 69435235 T DE69435235 T DE 69435235T DE 69435235 T DE69435235 T DE 69435235T DE 69435235 D1 DE69435235 D1 DE 69435235D1
Authority
DE
Germany
Prior art keywords
treatment
conditions
neuromuscular disorders
botulinum serotypes
various botulinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435235T
Other languages
English (en)
Inventor
Roger K Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to DE122009000066C priority Critical patent/DE122009000066I2/de
Application granted granted Critical
Publication of DE69435235D1 publication Critical patent/DE69435235D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69435235T 1993-06-10 1994-06-07 Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen Expired - Lifetime DE69435235D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122009000066C DE122009000066I2 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7504893A 1993-06-10 1993-06-10

Publications (1)

Publication Number Publication Date
DE69435235D1 true DE69435235D1 (de) 2009-10-15

Family

ID=22123211

Family Applications (6)

Application Number Title Priority Date Filing Date
DE69435235T Expired - Lifetime DE69435235D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435253T Expired - Lifetime DE69435253D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69435254T Expired - Lifetime DE69435254D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE122009000066C Active DE122009000066I2 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435284T Expired - Lifetime DE69435284D1 (de) 1993-06-10 1994-06-07 Behandlung neuromuskulärer Erkrankungen und Zustände mit verschiedenem Botulin-Serotyp
DE69429619T Expired - Lifetime DE69429619T2 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e

Family Applications After (5)

Application Number Title Priority Date Filing Date
DE69435253T Expired - Lifetime DE69435253D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69435254T Expired - Lifetime DE69435254D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE122009000066C Active DE122009000066I2 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435284T Expired - Lifetime DE69435284D1 (de) 1993-06-10 1994-06-07 Behandlung neuromuskulärer Erkrankungen und Zustände mit verschiedenem Botulin-Serotyp
DE69429619T Expired - Lifetime DE69429619T2 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e

Country Status (9)

Country Link
US (3) US6872397B2 (de)
EP (7) EP0702561B1 (de)
JP (4) JPH08511536A (de)
AU (1) AU689115B2 (de)
CA (3) CA2164866C (de)
DE (6) DE69435235D1 (de)
ES (5) ES2335281T3 (de)
HK (1) HK1061648A1 (de)
WO (1) WO1994028922A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
EP0702561B1 (de) * 1993-06-10 2002-01-09 Allergan, Inc. Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
DE69434610T2 (de) * 1993-12-28 2008-11-27 Allergan, Inc., Irvine Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK0773788T3 (da) * 1995-06-06 2003-09-01 Allergan Inc Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
EP1053014A4 (de) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGISCH AKTIVES HÄMAGGLUTININ VOM TYP A i(STRIDIUM BOTULINUM) UNDVERFAHREN ZU SEINER VERWENDUNG
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2004031355A2 (en) * 2002-10-01 2004-04-15 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
US7335367B2 (en) * 2003-03-06 2008-02-26 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
JP5089388B2 (ja) 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド 分解可能なクロストリジウム毒素
WO2006101809A1 (en) * 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DE602006017237D1 (en) 2005-04-05 2010-11-11 Allergan Inc Clostridientoxinaktivitätstests
WO2007014003A2 (en) 2005-07-22 2007-02-01 The Foundry Inc. Systems and methods for delivery of a therapeutic agent
US9511210B2 (en) 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
EP2001902B1 (de) 2006-03-14 2013-03-27 Allergan, Inc. Modifizierte clostridiale toxine mit geänderten targeting-fähigkeiten für die target-zellen von clostridialem toxin
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009123174A1 (ja) 2008-03-31 2009-10-08 財団法人化学及血清療法研究所 A2型ボツリヌス神経毒素製剤
CN102014779B (zh) 2008-05-09 2014-10-22 赫莱拉公司 用于治疗支气管树的系统、组件和方法
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
CN112089394A (zh) 2009-10-27 2020-12-18 努瓦拉公司 具有可冷却的能量发射组件的递送装置
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
WO2011060200A1 (en) 2009-11-11 2011-05-19 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
PL3242884T3 (pl) 2015-01-09 2021-08-16 Ipsen Bioinnovation Limited Kationowe neurotoksyny
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
CN109790204A (zh) 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
EP0702561B1 (de) * 1993-06-10 2002-01-09 Allergan, Inc. Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e
DE69434610T2 (de) 1993-12-28 2008-11-27 Allergan, Inc., Irvine Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen

Also Published As

Publication number Publication date
AU7087894A (en) 1995-01-03
DE69429619D1 (de) 2002-02-14
US20050129716A1 (en) 2005-06-16
DE69435284D1 (de) 2010-04-29
EP1508336B1 (de) 2009-11-18
EP1166793A1 (de) 2002-01-02
WO1994028922A1 (en) 1994-12-22
DE69435253D1 (de) 2009-12-31
DE69435254D1 (de) 2009-12-31
DE122009000066I2 (de) 2010-12-30
CA2310845C (en) 2001-05-15
EP1512411B1 (de) 2009-11-18
EP1099445A2 (de) 2001-05-16
AU689115B2 (en) 1998-03-26
CA2164866C (en) 2001-09-11
JP2005281317A (ja) 2005-10-13
US20020010138A1 (en) 2002-01-24
EP1941898A2 (de) 2008-07-09
EP1508336A1 (de) 2005-02-23
EP1941898B1 (de) 2010-03-17
JPH08511536A (ja) 1996-12-03
EP1374886B1 (de) 2009-09-02
CA2164866A1 (en) 1994-12-22
EP1374886A2 (de) 2004-01-02
EP0702561B1 (de) 2002-01-09
EP1374886A3 (de) 2004-02-11
EP1941898A3 (de) 2008-11-05
JP2010111703A (ja) 2010-05-20
JP2011256193A (ja) 2011-12-22
HK1061648A1 (en) 2004-09-30
DE122009000066I1 (de) 2010-02-04
US20010012833A1 (en) 2001-08-09
ES2335662T3 (es) 2010-03-31
ES2341140T3 (es) 2010-06-15
EP1512411A1 (de) 2005-03-09
CA2332406C (en) 2005-01-04
EP1099445A3 (de) 2001-09-05
ES2335281T3 (es) 2010-03-24
CA2310845A1 (en) 1994-12-22
CA2332406A1 (en) 1994-12-22
EP0702561A1 (de) 1996-03-27
ES2329232T3 (es) 2009-11-24
DE69429619T2 (de) 2002-09-12
US6872397B2 (en) 2005-03-29
ES2168302T3 (es) 2002-06-16

Similar Documents

Publication Publication Date Title
DE69435235D1 (de) Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
ATE218360T1 (de) Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
DE69220679D1 (de) Antibakterielles mittel und behandlung von gegenständen mit diesem
DE69435321D1 (de) Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE69130437D1 (de) Gerät mit neuronalen Netzwerken zur Detektion und Behandlung von Arrythmien
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69426690D1 (de) Behandlung von atrophischer Haut und Vagina
DE69422016T2 (de) Behandlung und entschwelfung von stahl in reformierungsverfahren mit niedrigem schwefelgehalt
DE69429160T2 (de) Behandlung von textilprodukt
DE69306335D1 (de) Prevention und Behandlung von Atherosclerosis
DE69306831D1 (de) Behandlung von Flüssigkeiten
DE69429259D1 (de) Behandlung von futtern und fasergut
DE69501944T2 (de) Arzneimittel zur Vorbeugung oder Behandlung von chronischem Rheumatismus und Sepsis
DE69318644T2 (de) Behandlung von Flüssigkeiten
AT400224B (de) Mittel zur behandlung und pflege von hufen
DE3881377T2 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
AU7319398A (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
DE69637316D1 (de) Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
DE69609820D1 (de) Verwendung von substituirten Pyridinverbindungen zur Behandlung der atopischen Dermatitis und der Kontaktdermatitis
DE9318429U1 (de) Mittel zur Abwehr und/oder Behandlung von Insektenstichen
DE9319102U1 (de) Pflanzliches Mittel zur Behandlung von Hämorrhoiden und analen Fissuren
DE59408477D1 (de) Therapieeinrichtung zur behandlung von leiden des herzens und herznaher gefässe
ATE432709T1 (de) Behandlung von diabetes

Legal Events

Date Code Title Description
R431 Request for term correction

Free format text: PRODUCT NAME: BOTULINUMTOXIN TYP B; REGISTRATION NO/DATE: EU/1/00/166/001-003 20010122

Spc suppl protection certif: 122009000066

Filing date: 20091012

Expiry date: 20140608

Extension date: 20160125

R071 Expiry of right

Free format text: PRODUCT NAME: BOTULINUMTOXIN TYP B; REGISTRATION NO/DATE: EU/1/00/166/001-003 20010122

Spc suppl protection certif: 122009000066

Filing date: 20091012

Expiry date: 20140608

Extension date: 20160125

R432 Decision on term correction now final

Free format text: PRODUCT NAME: BOTULINUMTOXIN TYP B; REGISTRATION NO/DATE: EU/1/00/166/001-003 20010122

Spc suppl protection certif: 122009000066

Filing date: 20091012

Expiry date: 20140608

Extension date: 20160125